Rapid Molecular Differential Detection of SARS-CoV-2
This technology is a PCR-based diagnostic method for rapid detection of SARS-CoV-2, influenza A and influenza B for a more accurate and sensitive diagnosis of a SARS-CoV-2 infection.
Unmet Need: COVID-Tests have a high false-negative rate
The SARS-CoV-2 virus has resulted in almost 600 million cases worldwide, and over 6 million deaths. The genome of the virus was publicly released in January 2020, and diagnostic assays were quickly developed for rapid viral detection. However, there are cases in which patients test negative for the virus, yet develop symptoms of disease, suggesting that a better assay is needed for detection of this virus.
The Technology: Diagnostic platform for accurate detection of SARS-CoV-2 and influenza A/B
This technology describes two assays that could be implemented as PCR assays for diagnosis of SARS-CoV-2. The first assay uses several primers to simultaneously detect SARS-CoV-2, influenza A, influenza B virus, and a housekeeping gene. The second assay uses several other primers to target three genes in SARS-CoV-2 and to target the housekeeping gene. Ultimately, this assay can differentially diagnose infections with symptoms resembling a SARS-CoV-2 infection, allowing for appropriate treatment and intervention.
Applications:
- Differential diagnosis of respiratory diseases
- Standard to measure different diagnostic methods
- Research tool for epidemiological studies
Advantages:
- Differentiates between COVID infections and flu infections
- Tests a variety of patient samples: nasopharyngeal, fecal and plasma
- Rapid turnaround time for results
Lead Inventor:
Patent Information:
Related Publications:
Tech Ventures Reference:
IR CU20260
Licensing Contact: Kristin Neuman